Engage Bio
“Cal Innovation Fund has offered invaluable strategic advice and made numerous introductions to leaders in our field. They are one of our highest value-add investors, and it's wonderful to work with other Cal alumni.”
—Kathryn Kwant, CSO and Co-Founder
Kathryn Strobel Kwant collaborated with Will Olson to turn her Cal Ph.D. research in molecular and biological engineering into new mRNA therapies that transform cancer cells into factories for locally acting immunotherapies. These therapies engage the immune system and redirect it to target cancer.
Given the success of mRNA-based vaccines and therapies during the Covid crisis, we are thrilled that Kathryn and Will are leveraging their expertise in these trends to develop new cancer treatments.